An International, Multicenter, Randomized Phase III Study of First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Versus First-Line Cisplatin/Gemcitabine Followed by Second-Line Erlotinib in Advanced Non–Small-Cell Lung Cancer: Treatment Rationale and Protocol Dynamics of the TORCH Trial-Reference-Cited by-同舟云学术

An International, Multicenter, Randomized Phase III Study of First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Versus First-Line Cisplatin/Gemcitabine Followed by Second-Line Erlotinib in Advanced Non–Small-Cell Lung Cancer: Treatment Rationale and Protocol Dynamics of the TORCH Trial

Published:2008-07 Issue:4 Volume:9 Page:235-238
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Gridelli Cesare,Butts Charles,Ciardiello Fortunato,Feld Ronald,Gallo Ciro,Perrone Francesco

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference20 articles.

1. Cancer Facts & Figures 2006;American Cancer Society,2006

2. EUROCARE-3 summary: cancer survival in Europe at the end of 20th century;Coleman;Ann Oncol,2003

3. Gemcitabine Plus Vinorelbine Compared With Cisplatin Plus Vinorelbine or Cisplatin Plus Gemcitabine for Advanced Non–Small-Cell Lung Cancer: A Phase III Trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group

4. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer;Schiller;New Engl J Med,2002

5. Chemotherapy for elderly patients with advanced non small cell lung cancer. The MILES (Multicenter Italian Lung cancer in the Elderly Study) phase 3 randomized trial;Gridelli;J Natl Cancer Inst,2003

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review;Cells;2021-05-14

2. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer;Cochrane Database of Systematic Reviews;2021-03-18

3. Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer;Exploration of Targeted Anti-tumor Therapy;2020-04-28

4. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations;Oncotarget;2016-12-03

5. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer;Cochrane Database of Systematic Reviews;2016-05-25